Company
Hyperfine
Last checked: Nov 19, 2026Source: SEC EDGAR, openFDA and ClinicalTrials.govMethods & limitations
FDA decisions since 2015
17
510(k), De Novo and PMA
Device trials
1
As lead sponsor, any status
Adverse event reports
0
Received Nov 1, 2025 to Nov 19, 2026
Recall records
0
One per recalled product
This company is not on our public-company list, so only this exact name is matched. Naming a company here is not a recommendation of it or of any security.
Financing
Public company. Figures from its SEC financial statements.
Listed
HYPR
Nasdaq · Hyperfine, Inc.
Public float
$44.2M
Value of shares held by non-insiders on Jun 30, 2025
Revenue
$13.6M
Fiscal year ending Dec 31, 2025
Net income
-$35.6M
Fiscal year ending Dec 31, 2025
R&D spending
$17.5M
Fiscal year ending Dec 31, 2025
Cash
$37.9M
As of Sep 30, 2026
Long-term debt
$13.4M
As of Sep 30, 2026
Shares outstanding
Not reported
Not in public filings: valuations, share prices and investors' names. Private databases such as PitchBook and Crunchbase estimate these from press releases and surveys. Not every round is filed: companies raising under other exemptions, or from foreign investors only, may not file Form D. Nothing here is investment advice.
Investors
5%+ shareholders from SEC Schedule 13D/13G filings since Dec 1, 2024, and SBIR/STTR grants (NIH through Nov 10, 2026, other agencies through 2023). Venture investors in private rounds are not in public filings.
The investor database is part of the paid tier
It is included for signed-in readers who have credit, along with the daily news digest. Credit is also what pays for AI device summaries.
Latest FDA decisions
The 8 newest of 17 since 2015.
K262622 · Decided Aug 19, 2026 · 22 days after receipt
Device type: System, Nuclear Magnetic Resonance Imaging (LNH) · Radiology & Imaging
K253489 · Decided Dec 12, 2025 · 49 days after receipt
Device type: System, Nuclear Magnetic Resonance Imaging (LNH) · Radiology & Imaging
K250236 · Decided May 30, 2025 · 123 days after receipt
Device type: System, Nuclear Magnetic Resonance Imaging (LNH) · Radiology & Imaging
K251276 · Decided May 21, 2025 · 27 days after receipt
Device type: System, Nuclear Magnetic Resonance Imaging (LNH) · Radiology & Imaging
K240944 · Decided Jul 16, 2024 · 102 days after receipt
Device type: System, Nuclear Magnetic Resonance Imaging (LNH) · Radiology & Imaging
K232760 · Decided Oct 6, 2023 · 28 days after receipt
Device type: System, Nuclear Magnetic Resonance Imaging (LNH) · Radiology & Imaging
K230208 · Decided Feb 22, 2023 · 28 days after receipt
Device type: System, Nuclear Magnetic Resonance Imaging (LNH) · Radiology & Imaging
- BrainInsight510(k)
K223268 · Decided Dec 16, 2022 · 53 days after receipt
Device type: Automated Radiological Image Processing Software (QIH) · Radiology & Imaging
Device trials
Trials on ClinicalTrials.gov that list this company as lead sponsor, most recently updated first.
NCT07296263 · 78 participants · Start Dec 30, 2025 · Primary completion Sep 15, 2026
Device: Portable MRI (pMRI) · For: Intra-axial Tumors; Extra-axial Tumors; Infection/Inflammatory Lesions
Sites: Altamonte Springs, Florida; Boston, Massachusetts; Amherst, New York · 6 sites in all
Reports received
0
Received Nov 1, 2025 to Nov 19, 2026
Malfunction reports
0
Injury reports
0
Death reports
0
Adverse event reports received per month
Reports that name this company as manufacturer, by the date FDA received them. The newest month is incomplete.
No reports to chart for this view.
Device types named most often
Last 12 months, by FDA product code. A company that sells more gets more reports.
No device types to rank.
Brand names named most often
Last 12 months, as written on the reports. One product can appear under several spellings.
No brand names to rank.
Recent recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recalls under this name in FDA's data.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.